BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37599554)

  • 1. Visual fixation suppression of caloric nystagmus in progressive supranuclear palsy - A comparison with Parkinson's disease.
    Naito R; Watanabe Y; Naito A; Sugasawa K; Nakata Y; Kamiyama T; Okiyama R; Yokochi F; Isozaki E; Yamasoba T; Takahashi K
    J Vestib Res; 2023; 33(6):385-401. PubMed ID: 37599554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy.
    Garbutt S; Riley DE; Kumar AN; Han Y; Harwood MR; Leigh RJ
    J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1386-94. PubMed ID: 15377682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy.
    Pagonabarraga J; Horta-Barba A; Busteed L; Bejr-Kasem H; Illán-Gala I; Aracil-Bolaños I; Marín-Lahoz J; Pascual-Sedano B; Pérez J; Campolongo A; Izquierdo C; Martinez-Horta S; Sampedro F; Kulisevsky J
    Parkinsonism Relat Disord; 2021 Apr; 85():63-68. PubMed ID: 33744691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Video-oculographic biomarkers for evaluating vertical ocular dysfunction in progressive supranuclear palsy.
    Quattrone A; Crasà M; Morelli M; Vescio B; Augimeri A; Gramigna V; Quattrone A
    Parkinsonism Relat Disord; 2022 Jun; 99():84-90. PubMed ID: 35642995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ocular motor abnormalities in progressive supranuclear palsy].
    Okuma Y; Nagashima T; Hirose K; Tanabe H; Tsubaki T; Mizuno M
    No To Shinkei; 1989 Feb; 41(2):125-32. PubMed ID: 2736143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease.
    Price S; Paviour D; Scahill R; Stevens J; Rossor M; Lees A; Fox N
    Neuroimage; 2004 Oct; 23(2):663-9. PubMed ID: 15488416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.
    Quattrone A; Morelli M; Nigro S; Quattrone A; Vescio B; Arabia G; Nicoletti G; Nisticò R; Salsone M; Novellino F; Barbagallo G; Le Piane E; Pugliese P; Bosco D; Vaccaro MG; Chiriaco C; Sabatini U; Vescio V; Stanà C; Rocca F; Gullà D; Caracciolo M
    Parkinsonism Relat Disord; 2018 Sep; 54():3-8. PubMed ID: 30068492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of torsional quick eye movements during head roll in progressive supranuclear palsy: a new diagnostic marker.
    Ling X; Kim HJ; Lee JH; Lee S; Choi JY; Zhong LQ; Yang X; Kim JS
    J Neurol; 2023 Apr; 270(4):2230-2236. PubMed ID: 36680570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.
    Tsukamoto K; Matsusue E; Kanasaki Y; Kakite S; Fujii S; Kaminou T; Ogawa T
    Neuroradiology; 2012 Sep; 54(9):947-55. PubMed ID: 22274571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflexive and volitional saccadic eye movements and their changes in age and progressive supranuclear palsy.
    Wright IH; Sekar A; Jensen MT; Hodgson M; Bancroft MJ; Koohi N; Lees AJ; Morris HR; Kaski D
    J Neurol Sci; 2022 Dec; 443():120482. PubMed ID: 36356484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
    Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
    Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).
    Swallow DMA; Counsell CE
    J Neurol; 2023 Jul; 270(7):3464-3474. PubMed ID: 36971841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Widespread diffusion changes differentiate Parkinson's disease and progressive supranuclear palsy.
    Talai AS; Sedlacik J; Boelmans K; Forkert ND
    Neuroimage Clin; 2018; 20():1037-1043. PubMed ID: 30342392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Salvatore C; Cerasa A; Castiglioni I; Gallivanone F; Augimeri A; Lopez M; Arabia G; Morelli M; Gilardi MC; Quattrone A
    J Neurosci Methods; 2014 Jan; 222():230-7. PubMed ID: 24286700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eye tracking identifies biomarkers in α-synucleinopathies versus progressive supranuclear palsy.
    Habibi M; Oertel WH; White BJ; Brien DC; Coe BC; Riek HC; Perkins J; Yep R; Itti L; Timmermann L; Best C; Sittig E; Janzen A; Munoz DP
    J Neurol; 2022 Sep; 269(9):4920-4938. PubMed ID: 35501501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deterioration of horizontal saccades in progressive supranuclear palsy.
    Terao Y; Fukuda H; Shirota Y; Yugeta A; Yoshioka M; Suzuki M; Hanajima R; Nomura Y; Segawa M; Tsuji S; Ugawa Y
    Clin Neurophysiol; 2013 Feb; 124(2):354-63. PubMed ID: 22883477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acoustical analysis of speech in progressive supranuclear palsy.
    Skodda S; Visser W; Schlegel U
    J Voice; 2011 Nov; 25(6):725-31. PubMed ID: 20457507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nystagmus in progressive supranuclear palsy: A neglected clinical feature?
    Klarendic M; Hribar M; Urbancic NB; Zupancic N; Kramberger MG; Trost M; Battelino S; Kaski D; Kojovic M
    Parkinsonism Relat Disord; 2021 Mar; 84():15-22. PubMed ID: 33517029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.